Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Work In Process (2017 - 2025)

Dexcom (DXCM) has disclosed Work In Process for 12 consecutive years, with $105.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Work In Process rose 273.67% to $105.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $105.0 million, a 273.67% increase, with the full-year FY2025 number at $105.0 million, up 273.67% from a year prior.
  • Work In Process was $105.0 million for Q4 2025 at Dexcom, up from $78.6 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $105.0 million in Q4 2025 to a low of $13.6 million in Q2 2021.
  • A 5-year average of $40.3 million and a median of $29.0 million in 2023 define the central range for Work In Process.
  • Peak YoY movement for Work In Process: fell 12.97% in 2023, then skyrocketed 273.67% in 2025.
  • Dexcom's Work In Process stood at $16.2 million in 2021, then grew by 6.17% to $17.2 million in 2022, then soared by 74.42% to $30.0 million in 2023, then decreased by 6.33% to $28.1 million in 2024, then surged by 273.67% to $105.0 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Work In Process are $105.0 million (Q4 2025), $78.6 million (Q3 2025), and $94.0 million (Q2 2025).